Equities research analysts expect Coherus Biosciences Inc (NASDAQ:CHRS) to announce earnings of ($0.90) per share for the current quarter, according to Zacks. Zero analysts have made estimates for Coherus Biosciences’ earnings. Coherus Biosciences posted earnings per share of ($1.71) during the same quarter last year, which would suggest a positive year-over-year growth rate of 47.4%. The company is scheduled to announce its next earnings report on Monday, March 12th.

On average, analysts expect that Coherus Biosciences will report full-year earnings of ($4.39) per share for the current financial year, with EPS estimates ranging from ($4.55) to ($4.23). For the next financial year, analysts anticipate that the firm will report earnings of ($2.91) per share, with EPS estimates ranging from ($3.10) to ($2.71). Zacks Investment Research’s EPS calculations are an average based on a survey of research firms that that provide coverage for Coherus Biosciences.

Coherus Biosciences (NASDAQ:CHRS) last announced its earnings results on Monday, November 6th. The biotechnology company reported ($1.09) EPS for the quarter, missing the consensus estimate of ($0.83) by ($0.26). Coherus Biosciences had a negative net margin of 73.89% and a negative return on equity of 582.31%.

Several research firms recently weighed in on CHRS. ValuEngine raised Coherus Biosciences from a “strong sell” rating to a “sell” rating in a research report on Friday, September 1st. Zacks Investment Research lowered Coherus Biosciences from a “hold” rating to a “sell” rating in a research report on Tuesday, October 10th. Maxim Group reissued a “buy” rating and set a $20.00 price target (down from $40.00) on shares of Coherus Biosciences in a research report on Friday, September 8th. Credit Suisse Group reissued an “outperform” rating and set a $17.00 price target (down from $24.00) on shares of Coherus Biosciences in a research report on Wednesday, September 27th. Finally, Cowen reissued an “outperform” rating and set a $45.00 price target on shares of Coherus Biosciences in a research report on Friday, September 8th. Three research analysts have rated the stock with a sell rating and eight have issued a buy rating to the company’s stock. Coherus Biosciences currently has a consensus rating of “Hold” and a consensus price target of $30.00.

A number of hedge funds have recently modified their holdings of the business. Jennison Associates LLC increased its position in Coherus Biosciences by 0.4% in the 2nd quarter. Jennison Associates LLC now owns 18,200 shares of the biotechnology company’s stock worth $261,000 after purchasing an additional 69 shares during the last quarter. Wells Fargo & Company MN increased its position in Coherus Biosciences by 0.9% in the 2nd quarter. Wells Fargo & Company MN now owns 29,116 shares of the biotechnology company’s stock worth $418,000 after purchasing an additional 253 shares during the last quarter. Legal & General Group Plc increased its position in Coherus Biosciences by 12.6% in the 2nd quarter. Legal & General Group Plc now owns 9,341 shares of the biotechnology company’s stock worth $134,000 after purchasing an additional 1,046 shares during the last quarter. California State Teachers Retirement System increased its position in Coherus Biosciences by 2.3% in the 2nd quarter. California State Teachers Retirement System now owns 67,940 shares of the biotechnology company’s stock worth $975,000 after purchasing an additional 1,500 shares during the last quarter. Finally, SG Americas Securities LLC increased its position in Coherus Biosciences by 32.7% in the 2nd quarter. SG Americas Securities LLC now owns 7,244 shares of the biotechnology company’s stock worth $104,000 after purchasing an additional 1,785 shares during the last quarter. 81.07% of the stock is currently owned by institutional investors.

Coherus Biosciences (CHRS) opened at $8.50 on Wednesday. Coherus Biosciences has a 52-week low of $8.05 and a 52-week high of $29.59. The company has a quick ratio of 5.46, a current ratio of 5.46 and a debt-to-equity ratio of 1.84.

ILLEGAL ACTIVITY NOTICE: This report was posted by American Banking News and is the sole property of of American Banking News. If you are accessing this report on another site, it was illegally stolen and republished in violation of United States and international trademark and copyright laws. The legal version of this report can be viewed at https://www.americanbankingnews.com/2017/12/06/0-90-eps-expected-for-coherus-biosciences-inc-chrs-this-quarter-2.html.

Coherus Biosciences Company Profile

Coherus BioSciences, Inc is a late-stage clinical biologics platform company. The Company is engaged in the business of developing and commercializing biosimilar products. The Company’s business is organized around therapeutic franchises, including Oncology biosimilar candidates pegfilgrastim (Neulasta) and bevacizumab (Avastin); Immunology (Anti-TNF) biosimilar candidates etanercept (Enbrel) and adalimumab (Humira); Ophthalmology biosimilar candidate ranibizumab (Lucentis), and Multiple sclerosis small molecule therapeutic candidate, CHS-131.

Get a free copy of the Zacks research report on Coherus Biosciences (CHRS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Coherus Biosciences Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Coherus Biosciences Inc and related companies with MarketBeat.com's FREE daily email newsletter.